154 related articles for article (PubMed ID: 35351104)
1. Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.
Gelfond JA; Hernandez B; Goros M; Ibrahim JG; Chen MH; Sun W; Leach RJ; Kattan MW; Thompson IM; Ankerst DP; Liss M
BMC Urol; 2022 Mar; 22(1):45. PubMed ID: 35351104
[TBL] [Abstract][Full Text] [Related]
2. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
4. Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators.
Liu X; Zhang Y; Duan H; Yang L; Sheng C; Fan Z; Liu Y; Gao Y; Wang X; Zhang Q; Lyu Z; Song F; Song F; Huang Y
Eur J Med Res; 2023 Jul; 28(1):257. PubMed ID: 37496058
[TBL] [Abstract][Full Text] [Related]
5. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.
Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
[TBL] [Abstract][Full Text] [Related]
7. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
[TBL] [Abstract][Full Text] [Related]
8. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Barrington WE; Schenk JM; Etzioni R; Arnold KB; Neuhouser ML; Thompson IM; Lucia MS; Kristal AR
JAMA Oncol; 2015 Jun; 1(3):342-9. PubMed ID: 26181184
[TBL] [Abstract][Full Text] [Related]
9. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
10. Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.
Liss MA; Al-Bayati O; Gelfond J; Goros M; Ullevig S; DiGiovanni J; Hamilton-Reeves J; O'Keefe D; Bacich D; Weaver B; Leach R; Thompson IM
Prostate Cancer Prostatic Dis; 2019 May; 22(2):244-251. PubMed ID: 30385837
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
13. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.
Shikany JM; Flood AP; Kitahara CM; Hsing AW; Meyer TE; Willcox BJ; Redden DT; Ziegler RG
Cancer Causes Control; 2011 Jul; 22(7):995-1002. PubMed ID: 21553078
[TBL] [Abstract][Full Text] [Related]
14. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
[TBL] [Abstract][Full Text] [Related]
15. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
17. Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.
Giri VN; Egleston B; Ruth K; Uzzo RG; Chen DY; Buyyounouski M; Raysor S; Hooker S; Torres JB; Ramike T; Mastalski K; Kim TY; Kittles R
Cancer Prev Res (Phila); 2009 Mar; 2(3):244-50. PubMed ID: 19240249
[TBL] [Abstract][Full Text] [Related]
18. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
19. Higher insoluble fiber intake is associated with a lower risk of prostate cancer: results from the PLCO cohort.
Shen Y; Yuan Q; Shi M; Luo B
BMC Public Health; 2024 Jan; 24(1):234. PubMed ID: 38243202
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
